TC-210 Treatment of refracilable mesotheliosis-positive solid tumors: Phase I/II clinical trials yielded positive results

Mesothytin (MSLN) is a specific expression of a variety of tumor surface of the subject protein, especially in pancreatic cancer (80% to 85%) led by a variety of solid tumors high expression, while the expression of normal tissue mesothytin is limited to the thoracic, heart wrap and peritina.
TCR2, a clinical immunotherapy company, today announced the results of a Phase I/II clinical trial from TC-210 (gavocabtagene autoleucel) for the treatment of mesotheliosis-positive solid tumors.
data as of November 24, 2020, three CASES were recorded in the first eight patients according to THEIST 1.1, while the first ovarian cancer patients received PR in the 6th month.
so far, only two patients have developed non-hematological graded toxicity associated with gawocabtagene autoleucel, and there is no evidence of neurotoxicity or non-tumor toxicity. Dr Garry Menzel, President and CEO of
TCR2 Therapeutics, said: "While the focus of any Phase I clinical trial is safety, the tumor retreat we observed using gawocabtagene autoleucel as a single drug supports our belief in TRuC-T cells.
most importantly, we are providing clinical and survival benefits to patients with highly pre-treated mesothelioma or ovarian cancer."
。